As we navigate the unprecedented challenges facing academic medicine and the U.S. health care system — funding uncertainty, threats to insurance coverage and more — it’s easy to feel discouraged. That’s why it is crucial for all of us at Johns Hopkins Rheumatology to remain laser-focused on the mission that has long been our north star: advancing the health of patients with rheumatic diseases and keeping our patients at the center of everything we do.
We are incredibly grateful for the generous support from the federal government, foundations, individual donors and the pharmaceutical industry, which enables us to pursue this important work. All of our funders share a commitment to our vision of decoding the underpinnings of rheumatic diseases, defining personalized treatment strategies and advancing human health. Taken together, their support is making it possible — in the face of formidable headwinds — for our team at Johns Hopkins Rheumatology to make leaps at improving the lives of patients with rheumatic diseases.
